Leerink Partnrs Predicts Kura Oncology Q1 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Kura Oncology in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst J. Chang expects that the company will post earnings of $0.15 per share for the quarter. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology’s FY2025 earnings at $0.15 EPS.

A number of other research firms have also weighed in on KURA. TD Cowen reissued a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Jefferies Financial Group lowered their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. UBS Group began coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. Wedbush increased their price objective on shares of Kura Oncology from $34.00 to $36.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Stock Performance

NASDAQ KURA opened at $8.79 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The business has a 50 day simple moving average of $8.69 and a two-hundred day simple moving average of $14.87. The stock has a market capitalization of $683.55 million, a PE ratio of -3.72 and a beta of 0.78.

Institutional Investors Weigh In On Kura Oncology

Hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company raised its holdings in shares of Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after acquiring an additional 1,976 shares in the last quarter. nVerses Capital LLC purchased a new position in Kura Oncology during the 3rd quarter valued at about $25,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Kura Oncology by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock valued at $288,000 after purchasing an additional 5,788 shares in the last quarter. Harbor Capital Advisors Inc. lifted its position in shares of Kura Oncology by 21.9% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company’s stock worth $924,000 after purchasing an additional 8,505 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Kura Oncology by 35.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock valued at $579,000 after purchasing an additional 7,722 shares in the last quarter.

Insider Buying and Selling at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,255 shares of company stock valued at $100,739 in the last quarter. 5.50% of the stock is owned by insiders.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.